The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases
Open accessAbstract
Sepsis remains the most common cause of death in intensive care units in the USA, with a current estimate of at least 750,000 cases per year, and 215,000 deaths annually. Despite extensive research still we do not quite understand the cellular and molecular mechanisms that are involved in triggering and propagation of septic injury. Endotoxin (lipopolysaccharide from Gram-negative bacteria, or LPS) has been implicated as a major cause of this syndrome. Inflammatory shock as a consequence of LPS release remains a serious clinical concern. In humans, inflammatory responses to LPS result in the release of cytokines and other cell mediators from monocytes and macrophages, which can cause fever, shock, organ failure and death. A number of different approaches have been investigated to try to treat and/or prevent the septic shock associated with infections caused by Gram-negative bacteria, including blockage of one or more of the cytokines induced by LPS. Recently several novel amphipathic compounds have been developed as direct LPS antagonists at the LPS receptor, TLR4. This review article will outline the current knowledge on the TLR4-LPS synthesis and discuss the signaling, in vitro pre-clinical and in vivo clinical evaluation of TLR4 antagonists and their potential use in sepsis and a variety of diseases such as atherosclerosis as well as hepatic and renal malfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394 · cited 3×
“These motifs are known as pathogen-associated molecular patterns (PAMPs) (2).”
BackgroundThe family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667
Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction
Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., & Gusovsky, F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10689 · Cited by 1,924
Negative regulation of Toll-like receptor-mediated immune responses
Liew, F. Y., Xu, D., Brint, E. K., & O'Neill, L. A. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1630 · Cited by 1,509
Epidemiology of sepsis: an update
Angus, D. C., & Wax, R. S. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00035 · Cited by 813 · cited 1×
“Sepsis is a major cause of high mortality rate in intensive care units in the USA (71) .”
BackgroundOpal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609 · cited 1×
“These plasma levels are still >100-fold that found in even the most extreme cases of human sepsis (65).”
BackgroundFort, M. M., Mozaffarian, A., Stöver, A. G., Correia, J. D. S., Johnson, D. A., Crane, R. T., Ulevitch, R. J., Persing, D. H., Bielefeldt-Ohmann, H., Probst, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6416 · Cited by 216
Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14 + Monocytes
Methe, H., Kim, J.-O., Kofler, S., Nabauer, M., & Weis, M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000168410.44722.86 · Cited by 172
Cited by
Alcoholic liver disease: mechanisms of injury and targeted treatment
Louvet, A., & Mathurin, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.35 · Cited by 855
Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy
Lin, M., Yiu, W. H., Wu, H. J., Chan, L. Y. Y., Leung, J. C. K., Au, W. S., Chan, K. W., Lai, K. N., & Tang, S. C. W. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111210 · Cited by 386
Vezzani, A., Maroso, M., Balosso, S., Sanchez, M.-A., & Bartfai, T. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.03.018 · Cited by 362
The enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3
Greenhill, C. J., Rose-John, S., Lissilaa, R., Ferlin, W., Ernst, M., Hertzog, P. J., Mansell, A., & Jenkins, B. J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002971 · Cited by 264
Metadata
- Authors
- Leon, C. G., Tory, R., Jia, J., Sivak, O., & Wasan, K. M.
- Venue
- Pharmaceutical Research
- Published
- 2008-05-21
- Volume
- 25
- Issue
- 8
- Pages
- 1751-1761
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2008793028
- Cited by
- 174
- References
- 8
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases. https://app.cochat.ai/papers/10.1007/s11095-008-9571-x
- The paper
- Leon, C. G., Tory, R., Jia, J., Sivak, O., & Wasan, K. M. (2008). Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases. Pharmaceutical Research. https://doi.org/10.1007/s11095-008-9571-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.